Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Yohann Loriot

Citation

Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Authors

Y. Loriot1, S. Van Sanden2, J. Diels3, N. Rahhali4, D. Seshagiri5, B. KOWALSKI6, S. Fleming7, P. De Porre8, A.O. Siefker-Radtke9

Author affiliations

  • 1 Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 2 Hemar Emea Department, Janssen Pharmaceutica NV - Belgium, 2340 - Beerse/BE
  • 3 Hemar Emea Department, Janssen Pharmaceutica NV - Belgium, 2340 - Beerse/BE
  • 4 Hemar Emea Department, Janssen Cilag France, xxxx - Issy Les Moulineaux/FR
  • 5 Hemar Emea Department, Janssen-Cilag Germany, 41470 - North Rhine-Westphalia/DE
  • 6 Health Economy, Janssen Cilag France, xxxx - Issy Les Moulineaux/FR
  • 7 Oncology, Janssen R&D US, 08560 - Titusville/US
  • 8 Clinical Oncology, Janssen R&D, Belgium, 2340 - Beerse/BE
  • 9 Ongology, MD Anderson Cancer Center, 77030 - Houston/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3246

Background

Erda, a pan-fibroblast growth factor receptor (FGFR) inhibitor recently received accelerated US FDA approval for locally advanced or metastatic urothelial cancer (mUC) in adult patients (pts) with FGFR2/3 alterations who progressed on ≥ 1 prior platinum-containing chemotherapy, based on a single-arm phase 2 study. In the absence of head-to-head studies, a matching-adjusted indirect comparison (MAIC) was used to compare the efficacy of erda relative to available therapies in mUC pts.

Methods

Systematic literature review was performed to identify published randomized controlled trials (RCTs) of 2nd-line treatments (from 1990-on) in mUC pts with unknown FGFR status. Individual patient-level data (IPD) were used from the phase 2 study (NCT02365597) in mUC pts treated with erda (8 mg/day). ORR (primary endpoint), overall survival (OS) and progression-free survival (PFS) were compared using an unanchored MAIC. The IPD were weighted to match the aggregated data from comparator studies.

Results

Nine relevant RCTs of 6 comparators (docetaxel [D], vinflunine [V], pembrolizumab [Pb], atezolizumab [A], paclitaxel [P], and mixed-chemotherapy [D, V or P]) that were identified could be matched with. The matching-adjusted odds ratios (OR) for ORR were consistently >1 vs all comparators, suggesting higher ORR with erda treatment over all comparator 2nd-line therapies. The matching-adjusted hazard ratios (HRs) for OS and PFS vs all comparators were <1, suggesting better outcomes (PFS/OS) with erda. Results from the sensitivity analyses showed varied statistical significance, however, the overall trends were relatively similar. Study limitations: availability of comparable endpoints and baseline characteristics; small sample size of the erda study.Table:

926P MAIC results for base case scenario: Erda (in FGFR+ pts) vs available 2nd-line therapies in pts with unknown FGFR status

ComparatorStudyN (Neff)ORR (OR [95% CI])OS (HR [95% CI])PFS (HR [95% CI])
PembrolizumabNCT0225643679 (40)2.26 [1.11; 4.59]*0.61 [0.37; 0.99]*0.77 [0.58; 1.03]
AtezolizumabNCT0230280774 (45)6.80 [3.55; 13.02]***0.58 [0.37; 0.92]*
Mixed-chemotherapyNCT0225643679 (45)4.15 [2.04; 8.46]***0.54 [0.35; 0.85]**0.77 [0.56; 1.07]
Mixed-chemotherapyNCT0230280774 (51)6.26 [3.37; 11.63]***0.54 [0.34; 0.84]**
DocetaxelaNCT0128246368 (45)3.71 [1.11; 12.35]*0.72 [0.41; 1.25]0.51 [0.32; 0.80]*
DocetaxelNCT0088033478 (42)3.98 [1.48; 10.74]**0.52 [0.31; 0.87]*0.84 [0.56; 1.26]
DocetaxelNCT0178054584 (47)6.02 [2.48; 14.63]***0.37 [0.23; 0.61]***
DocetaxelNCT0242612578 (63)3.46 [1.80; 6.66]**0.63 [0.47; 0.84]*
VinflunineaNCT0031523778 (53)4.74 [2.21; 10.18]***0.57 [0.39; 0.84]**
VinflunineNCT0183023161 (32)1.51 [0.45; 5.10]0.49 [0.24; 0.99]*0.96 [0.51; 1.81]
PaclitaxelaNCT0094945568 (44)2.63 [1.03; 6.73]*0.59 [0.37; 0.95]*0.95 [0.64; 1.41]
*

p ≤ 0.05;

**

p ≤ 0.01;

***

p ≤ 0.0001

For most comparators, only the main characteristics (according to clinical experts; number of risk factors, ECOG, liver metastases, hemoglobin<10g/dl, visceral disease, liver/bone metastasis, metastatic disease, primary tumor site, smoking status, and time since prior therapy) were included in the base case matching process to maintain a reasonable effective sample size (Neff). aAll available characteristics were included. When type of ORR (assessment by independent review committees [IRR] or assessment by investigators) is not specified for the comparator study, IRR was used for erda as this leads to conservative results.

Conclusions

Treatment of FGFR+ mUC pts with erda may be associated with improved overall response, PFS and OS as compared to available therapies in pts with unknown FGFR status.

Clinical trial identification

NCT02365597.

Editorial acknowledgement

Priya Ganpathy, MPharm, ISMPP CMPP™ (SIRO Clinpharm Pvt. Ltd, India) provided writing assistance and Harry Ma, PhD (Janssen Global Services) provided additional editorial support.

Legal entity responsible for the study

Janssen Research & Development, LLC.

Funding

Janssen Research & Development, LLC.

Disclosure

Y. Loriot: Honoraria (self), Consultancy / Advisory Role- Astellas Pharma, AstraZeneca, Janssen, Merck Sharp & Dohme, Pfizer, Roche, Ipsen, Seattle Genetics, Sanofi; Research Funding- Sanofi (Inst) S. Van Sanden: Shareholder / Stockholder / Stock options, Employee and stockholder: Janssen Research & Development. J. Diels: Shareholder / Stockholder / Stock options, Employee and Share holder: Janssen Reserach & Development. N. Rahhali: Shareholder / Stockholder / Stock options, Employee and stockholder: Janssen Research & Development. D. Seshagiri: Shareholder / Stockholder / Stock options, Employee & stockholder: Janssen Reserach & Development. B. Kowalski: Shareholder / Stockholder / Stock options, Employee & stockholder: Janssen Research & Development. S. Fleming: Shareholder / Stockholder / Stock options, Employee & stockholder: Janssen Research & Development. P. De Porre: Shareholder / Stockholder / Stock options, Employee & stockholder: Janssen Research & Development. A.O. Siefker-Radtke: Consulting / Advisory Role: AstraZeneca, Bristol-Myers Squibb, Eisai, EMD Serono, Genentech, Inovio Pharmaceuticals, Janssen, Lilly, Merck, NCCN; Speakers’ Bureau: Genentech; Research funding: Bristol-Myers Squibb, Janssen, Michael, Sherry Sutton; Fund for Urothelial Cancer: NIH, Takeda; Patents / Royalties / Other Intellectual Property: Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.